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Abstract: 
For the development of specific immunological assays, the binding of a specific antibody (Ab) to 
the target antigen (Ag) has to be relatively strong. In this study, we have utilized affinity 
capillary electrophoresis (ACE), a form of capillary zone electrophoresis (CZE) to determine the 
binding constant (Kb) of specific Abs against bovine serum albumin (BSA) and the healthy prion 
protein (PrPc), in buffer solutions at fixed pHs, approximating in vivo conditions. We have also 
utilized capillary isoelectric focusing (cIEF) to determine the complexity and recognition of the 
various isoforms of PrPc Abs towards their Ag, PrPc. Only ACE and CZE have been used to 
derive Kb values. The selected Abs for the prion protein can recognize both healthy and diseased 
states of the protein and are commercially available. The Kb values of PrPc Abs appear to be as 
strong as the anti-BSA (Ab to BSA) and other reported Kb values for proteins of similar size to 
PrPc. This appears to be one of the few reports on Kb values for any PrPc Abs, and their 
applications for in vitro immunoassays (e.g., enzyme-linked immunosorbent assays (ELISAs)). 
Such assays are being used to detect the infectious agent, PrPres, in brain and related 
matter/tissues. 
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Article: 
1. Introduction 
Within the past few decades, there has arisen a significant interest in the development of new and 
sensitive assays for the presence of infectious prion proteins, termed PrPres (enzyme resistant 
form of the healthy, PrPc (cellular or native form)) [1], [2], [3], [4], [5], [6], [7], [8], [9] and [10]. 
PrPres signifies the infectious or diseased agent, that species of the prion protein responsible for 
all tissue spongiform encephalopathies (TSEs). It should be indicated that PrP is an ambiguous 
term, it does not really define if one is working with PrPc or PrPres forms. Hence, throughout 
this paper, we have used PrPc to describe the actual protein being studied, the native or healthy 
species. None of this work was done using the infectious species, PrPres. 
Numerous analytical methods, mainly enzyme-linked immunosorbent assays (ELISAs), have 
been developed. Some of these assays are commercially available and applied daily around the 
world [11], [12],[13], [14], [15], [16] and [17]. Virtually all of these are post-mortem assays, 
requiring the death of the animal or person and removal of brain, spinal column, pituitary gland, 
and/or related tissues for analysis of PrPres. There are some newer assays, recently described, 
that appear successful, ante-mortem. The term ante-mortem relates to tests performed on a 
subject's biofluids (urine, blood, tears, etc.) while the animal/human is still alive, hence before-
death. However, none of these are applied on a routine basis to large numbers of 
animals [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29], [30], [31], [32], [33], [3
4], [35], [36],[37], [38], [39], [40], [41] and [42]. Perhaps only the Gabizon and Schmerr 
approaches will be applicable ante-mortem, with any degree of specificity for PrPres, in 
biofluids [18], [19], [23], [24], [25], [26], [27],[28] and [29]. Those approaches recently 
described by Saborio and co-workers [20] and [21] and Prusiner's group [32], as well as the 
method of Cashman's group [36], may utilize more PrPres specific Abs, but it is not yet clear 
they will be applicable ante-mortem [16] and [17]. 
In all of the above approaches, the preferred mode of detection is based on the ELISA format, 
using various Abs for PrPres. There are numerous other immunological approaches on the 
market today [15],[16] and [17], but none of these appear usable, ante-mortem in simple 
biofluids. They are used post-mortem, on the brain matter from dead animals or people, as the 
preferred source of analyte. There are, at least, two crucial features of Abs that relate to their 
utility in any ELISA, one being their antigen (Ag) specificity and the other, their binding 
properties for the PrPres protein. Ideally, one wants an Ab that will only recognize the PrPres 
species, and totally ignore the healthy, PrPc form. It would appear that only the Prusiner and 
Cashman groups have such potentially, very useful Abs. However, those Abs only improve 
specificity and reduce sample preparation requirements (obviating the need to use proteinase K 
to eliminate PrPc from an infected sample, leaving only PrPres to be detected). Such highly 
specific Abs do not automatically lower limits of detection (LODs), they just reduce the 
complexity of sample preparation. Improved LODs can be realized by changing the nature of the 
ELISA format (e.g., immuno-polymerase chain reaction or i-PCR) [43]or by improving 
the Kb values for existing Abs. Using those Abs that already have strong Kb values could also 
lower LODs. It appears to be difficult to improve Kb values for existing Abs, and thus efforts are 
needed to generate Abs with native, higher Kb values, if possible. 
Though there are numerous publications that deal with the determination of Kb values, very few 
of these relate to prion Abs [44]. And, even fewer of these deal with Ab–Ag Kb values, similar to 
the work being presented here [45]. We have been interested in determining the Kb values for 
existing, commercial Abs, so that future immunoassays would utilize such Abs, perhaps to the 
exclusion of others. It is possible that one of the Abs being described herein has already been 
used to develop a commercialized assay for PrPres. It would appear that there is very little in the 
literature describing absolute Kb values for any prion Abs, other than for Prusiner's 
work [32], [33], [34] and [35]. We have recently described, along with others, the application of 
ACE for the determination of Kb values for small drugs and large proteins (e.g., 
BSA) [48],[49] and [50]. The application of ACE methods for Ab–protein binding has been 
described much less than for Ab–small molecules. In these approaches, one can introduce either 
the Ab or its Ag into the buffer, at varying concentrations, and inject the same concentration of 
the corresponding partner (Ag or Ab). 
There are numerous approaches for the determination of Kb values, such as frontal 
chromatography, frontal CE, ultracentrifugation, surface plasmon resonance spectroscopy 
(Biacore), affinity stoichiometry, and others [46], [47], [48], [49], [50], [57] and [58]. There are 
several ways by which ACE can be configured to provide binding or association constants (Kb) 
for proteins and their Abs. ACE has also, at times, been termed immunoaffinity CE (IACE), 
wherein an Ab and its Ag are involved [46], [47], [48], [49] and [50]. Most ACE methods rely on 
changes in the apparent mobility of either the Ab or the Ag, when one or the other is added to the 
CE buffer in varying concentrations. As the partner being injected (at constant concentration) 
sees or recognizes increasing concentrations of its binding partner in the buffer, the original 
injected partner's mobility will change. And, it can change in either direction, towards longer or 
shorter migration times [versus an internal standard marker, often dimethyl sulfoxide (DMSO) or 
dimethyl formamide (DMF)], depending on how the charge/mass ratio of the Ab–Ag complex 
differs from the charge/mass of the injected species alone (Ab or Ag). The Kb determined should 
be independent of which partner is injected and which is contained in the run buffer. The theory 
of ACE for determining Kb values has been described in numerous publications, and rather than 
repeat what is already in the literature, we will summarize the salient points of the technique and 
theory, as below (Sections 2 and 3). It is also possible to first mix Ab and Ag outside of the 
capillary, as a function of time, until a true equilibrium is reached, and then inject that mixture 
into the ACE system. Changes in the peak heights/areas for either Ab or Ag partner or the 
complex(es) formed (Ab–Ag) can then be used to derive Kb values via the usual Scatchard 
plots [47], [48], [49] and [50]. This is really a capillary zone electrophoresis (CZE) method and 
not a form of ACE, and the parameter for quantitation is peak height or area, but not changes in 
migration times. 
We describe here the application of an ACE method to determine Kb values for several 
commercial Abs for PrPc protein and BSA, in the hope of discovering Abs that may have 
stronger Kb values than otherwise. Stronger Kb values should then lead to improved (stronger) 
binding (large on and small off rates) and lower LODs, in the ELISA format. The combination of 
improved specificity for only the PrPres species and improved Kb values, in newer forms of 
ELISAs (e.g., i-PCR), should ultimately, lead to successful ante-mortem assays in biofluids. At 
least, that is the ultimate goal for many trying to develop any ante-mortem prion assays today. 
In comparing cIEF with ACE, these are two quite different CE approaches for protein analysis 
and/or characterization. ACE is really used only to determine Kb values, it is not used to 
demonstrate purity or identity, but rather it is a kinetic method for measuring equilibrium 
constants. cIEF, on the other hand, is a true CE protein identification mode or technique, it does 
not provide Kb values, but rather it provides pIinformation and a demonstration of the complexity 
of a protein sample [number and isoelectric points (pIvalues) of all isoforms separable by cIEF]. 
It can also be used to demonstrate protein purity, and, as here, affinity or recognition of an Ab 
towards its Ag. It can also be used to show shifts in migration times and mobilities as an Ab 
complexes with one or more of the possible Ags present in the sample. cIEF can also be used to 
show the recognition of an Ab for its Ag, and even to show the formation of the various Ab–Ag 
complexes possible (1:1 and 2:1, etc.). Both cIEF and ACE have found widespread applicability 
in protein analysis and characterization. 
2. Experimental 
2.1. Chemicals and reagents 
The BSA and goat BSA Ab (polyclonal) were from Sigma (St. Louis, MO, USA). The 
recombinant prion protein was obtained from Calbiochem (EMD Biosciences, La Jolla, CA, 
USA). The Rubenstein Ab (01-16/6BIO) was obtained from Dr. Richard Rubenstein and Dr. 
Richard Kascsak at the NYS Institute of Basic Biomedical Research (Staten Island, NY, USA). 
The VMRD Ab was obtained from VMRD (Pullman, WA, USA), and the PolyLC prion Ab was 
from PolyLC Co. (Columbia, MD, USA), through the kind assistance of Dr. A. Alpert. The 
pI markers (proteins) and the mobilizer buffer were obtained from Bio-Rad (Hercules, CA, 
USA). The Z1-CH3 reagent was obtained from Waters (Milford, MA, USA). The ImmunoPure 
Plus Immobilized Protein G packing and the ImmunoPure binding/elution buffer systems were 
obtained from Pierce (Rockford, IL, USA). The concentrating and desalting steps were 
performed with a Millipore Microcon centrifugal filter and microcentrifuge (Millipore, Bedford, 
MA, USA). 
2.2. Apparatus 
All of the CE experiments were carried out with a Waters Quanta 4000 instrument equipped with 
a UV detector. The Beckman eCAP cIEF 3–10 kit (Beckman–Coulter, Fullerton, CA, USA) was 
used for the cIEF experiments. The bare fused silica capillary was obtained from Polymicro 
Technologies (Phoenix, AZ, USA). 
2.3. Purification of the antibodies 
All of the Abs being studied were purified after receipt from the supplier, using standard, 
immunoaffinity methods and filtration procedures, as provided by the vendors (Pierce) or 
available literature [59], [60], [61],[62], [63], [64] and [65]. These involved the use of 
commercial Protein G immunoaffinity columns, as well as commercial binding and elution 
buffers (Pierce). Initial filtration or desalting of all Abs, as received or after immunoaffinity 
purification, was performed using centrifugal filters of regenerated cellulose [molecular mass 
cut-off (MWCO = 100,000)], designed for Ab isolation (Millipore). Specific protocols were 
provided by the vendors [62]. 
2.4. Buffer and sample preparation 
For the cIEF work, a 4 μl eCAP cIEF 3–10 Ampholyte was put into 200 μl of the cIEF gel 
along with the pImarkers, and the components were fully homogenized. The anolyte was 91 mM 
phosphoric acid in cIEF gel and the catholyte was 20 mM sodium hydroxide in water. A neutral, 
coated capillary from Beckman–Coulter, cut to 32 cm (24.5 cm to detector window) × 50 μm 
i.d., was used as the separation column. The detection wavelength was 280 nm. The analyte was 
focused at 15 kV for 6 min, and then mobilized at 22 kV with a cathodic mobilizer (Bio-Rad). 
The ACE experiments were performed with a bare, fused silica capillary, 50 cm (43 cm to 
detector) × 50 μm i.d. The running buffer consisted of 50 mM of sodium phosphate and 1.0 M 
of Z1-CH3 zwitterion, that was used for eliminating capillary wall adsorption of proteins. 
Various concentrations of Ab (receptor) or protein (ligand, L) were added into the running buffer 
when desired. The monitored protein/Ab injection solution contained 0.001% DMF, which was 
used as a neutral EOF marker (DMSO and mesityl oxide are other possible markers). The 
samples were hydrostatically injected for 10 s. Ten kilowatts of high voltage was applied for the 
electrophoresis, and detection was set at 214 nm UV. 
2.5. Determination of Kb values by ACE 
Basically, the change in mobilities of the receptor (A) (species injected into the running buffer) is 
a function of the ligand (B) concentration in the sample. With reference to the internal standard, 
the changes in the electrophoretic mobility (dμA) of the receptor are measured, in the absence 
and then presence of the ligand (B) at various concentrations. Depending on the strength of Kb, 
the dμA can be large or small. Hence, there is a direct relationship between dμA and Kb, which 
is the basic premise of using ACE to measure Kb values. In order to remove the effect of changes 
in electroosmotic flow (EOF), resulting from changes in the receptor concentration added to the 
running buffer, the relative mobility change should be used to replace simple mobility changes. 
The relative mobility change is slightly different from the absolute mobility change, in that it 
utilizes the EOF in the presence and absence of various concentrations of the binding species 
added to the running buffer. The relative mobility change, DμA, should thus be used to replace d
μA. DμA is defined as: 
 
where μAB and μA are the mobilities of the receptor–ligand complex and receptor alone, 
respectively, andμeof,A and μeof,B are the EOFs in the absence and presence of various 
concentrations of that species added to the running buffer, respectively. 
According to the Scatchard theory: 
 
where [B] is the concentration of the ligand (B), and DμAmax is the relative mobility change of 
receptor when it is saturated with the ligand. 
3. Results and discussion 
3.1. cIEF of antibodies and their complexes 
We have now used cIEF in order to discern the heterogeneity of isoforms present in various 
prion Abs [51],[52], [53], [54], [55] and [56]. This use of cIEF has been reported before for other 
Abs, though apparently never for any prion related species. A typical electropherogram for the 
BSA Ab is given in Fig. 1, with a final concentration in the cIEF buffer of 0.5 mg/mL. Fig. 1A is 
the electropherogram of the intact BSA Ab, polyclonal, which shows the presence of numerous 
isoforms, which could not be better separated under any cIEF conditions we evaluated. In Fig. 
1B, we mixed BSA and its Ab, using 30 μl of an Ab concentration of 0.5 mg/mL and 10 μl of 
1 mg/mL BSA solution. The resulting mixture was then mixed with 60 μl of the Beckman 
ampholyte kit (Section 2). The molar ratio of Ab:Ag in Fig. 1B was roughly 2:3, with an excess 
of the Ag, BSA. The BSA peak appears to the right of the complex peaks (not the spike peak), 
both in Fig. 1B and C. The multiple peaks that corresponded to the immunocomplexes in Fig. 1B 
and C were presumably derived from the isoforms of the Ab combining with one or two 
molecules of the BSA Ag. Other complexes are also possible. There did not appear to be any 
remaining isoforms of the Ab in Fig. 1B or C, suggesting that all were active and bound to the 
Ag. In Fig. 1C, 30 μl of a 0.5 mg/mL Ab and 20 μl of a 1 mg/mL BSA were mixed with 60 μl 
of the ampholyte gel. In this case, the molar ratio was about 1:3 for Ab:BSA species. We can 
observe that the excess, uncomplexed BSA peak (far right peak) has become larger than in Fig. 
1B. The pattern of peaks for the complexes has changed somewhat, perhaps because more 2:1 
species are present in Fig. 1C. It would appear that the immunocomplex peaks having lower 
pI values (more acidic) have become dominant herein. This is reasonable, since BSA is an acidic 
protein and its Ab is more basic. As more and more BSA became bound to its Ab, the complexes 
should have smaller pI values and the immunocomplexes would become more acidic. 
 
Fig. 1. cIEF electropherograms of goat anti-BSA Ab and its BSA complexes. (A) goat anti-BSA 
Ab alone; (B) Ab and BSA mixture, molar ratio of 2:3; (C) Ab and BSA mixture, molar ratio of 
1:3. Specific conditions indicated in Section 2. 
Fig. 2A is the electropherogram of the BSA Ab with pI markers of 7.9, 5.9, and 4.6, and Fig. 2B 
is the electropherogram of free BSA and its immunocomplexes with the same pI markers. The 
pI values of the BSA Ab and its immunocomplexes could be determined from these 
electropherograms, by using a standard calibration plot for the three pI markers [51]. For the 
BSA Ab, its pI values were from 5.9 to 7.0, and for the BSA immunocomplexes, the pI values 
were from 5.2 to 5.8. When BSA alone was injected with these same pI markers, its pI was found 
to be about 4.6. This further confirmed the above assertion that the complexes should have lower 
pI values and be more acidic than the free Ab isoforms (Fig. 1A). 
 
Fig. 2. cIEF of goat anti-BSA Ab and its BSA complexes, together with pI markers. (A) Ab and 
markers of pI values, 7.9, 5.9, and 4.6; (B) Ab, BSA, and pI markers, as in (A). The pI range of 
the Ab was 5.85–7.00, and the pI range of the complexes was 5.24–5.75. Specific conditions 
indicated in Section 2. 
However, the main thrust of this paper is to describe the cIEF and ACE of commercially 
available prion Abs. Thus, Fig. 3A illustrates the cIEF electropherogram of a polyclonal, PolyLC 
prion Ab. There are, of course, numerous Abs to the prion protein, many of which are not 
commercially available. The cIEF pattern for these isoforms is very similar to that for the BSA 
Ab, but the pI values here are somewhat lower. Using again three internal standard proteins, as 
in Fig. 2B, we could determine the pI range in Fig. 3A to be from 5.2 to 6.9. When this PolyLC 
Ab was mixed with PrPc, a mixture of immunocomplexes was formed, Fig. 3B. The first set of 
peaks, those having shorter migration times, were due to the newly formed Ab–prion complexes. 
The second set of peaks, those with longer migration times, arose from the excess prion Ab 
present. The pIvalues of the complexes shifted to a more basic region (shorter migration times), 
since the prion protein was a basic protein, having a higher pI value than its Ab. The pI values 
for this commercial, recombinant prion protein were determined, Fig. 4, but now using cIEF with 
a different set of pI marker proteins. There were several major peaks for this recombinant prion 
protein (Calbiochem), with the two largest peaks (i.e., 2 and 3) having pI values of 8.4 and 8.6. 
We believe that the recombinantly formed PrPc has more than one isoform, and that these may 
well be post-translational modifications arising from the cells used to express the protein. 
Presumably, all of these isoforms represent Ab active species, though we have not conclusively 
demonstrated this. That could also be done by cIEF methods. The MALDI (matrix-assisted laser 
desorption/ionization)-TOF-MS (time-of-flight mass spectrometry) mass spectrum for this 
sample showed only a single peak, at the correct molecular mass (Mr) of the known prion protein 
structure (data not shown). 
 
Fig. 3. (A) cIEF electropherogram of Poly LC anti-prion protein, specific conditions as indicated 
elsewhere (Section 2); (B) cIEF electropherogram of a mixture of Poly LC anti-prion Ab and the 
prion protein. The first set of peaks, those having shorter migration times, corresponded to the 
complexes. Specific conditions indicated in Section 2. 
 
Fig. 4. cIEF electropherogram of Calbiochem prion protein, with pI markers of 9.3, 7.9, 6.6; 
peaks 2–3 were from the prion protein. pI values for peaks 2 and 3 were 8.6 and 8.4, 
respectively. Specific conditions indicated in Section 2. 
The cIEF isoform pattern for a monoclonal Ab should be much simpler than for polyclonal 
species [51]. Thus, Fig. 5 illustrates the electropherogram of a noncommercial, monoclonal prion 
Ab, termed here 6BIO by the Rubenstein/Kascsak group at NYS-IBR. Six isoforms were well 
separated under these cIEF conditions, with a pI range from 6.3 to 6.6, much narrower than for 
the polyclonal Abs above (BSA and prion). Fig. 6 is the cIEF electropherogram of a VMRD 
prion Ab, also a monoclonal Ab. Two major peaks (numbers 2 and 3) were observed, with pIs 
determined as 7.19 and 7.13, again using three internal standard, protein markers, as indicated 
in Fig. 6. This prion Ab was slightly more basic than the other two prion Abs studied. The 
presence of the Ab peaks in this sample was determined by injecting a blank mixture of just the 
three internal standard, protein markers in the absence of the Ab. The only difference here was 
the lack of appearance of peaks 2 and 3 in Fig. 6. The other peaks at migration times 18.0–
21.0 min were presumably due to impurities in the internal standard proteins. 
 
Fig. 5. cIEF of the Rubenstein (NYS-IBR) 01-16/6BIO monoclonal anti-prion Ab, with pI values 
in the range of 6.3–6.6. Specific conditions indicated in Section 2. 
 
Fig. 6. cIEF electropherogram of the VMRD anti-prion Ab, peaks 1, 4, and 6 were markers of 
pI values 7.9, 6.6, and 4.6, respectively; peak 5 was BSA, and peaks 2–3 were the Ab peaks. 
Specific conditions indicated in Section 2. 
3.2. ACE Determination of Kb values for antibodies (Abs) and protein antigens (Ags) 
We are measuring Kb at equilibrium, using ACE or other analytical methods, which is really 
equal to the equilibrium association constant, Ka. There is general consensus that Kb is equal 
to Ka, at equilibrium, which is not the same thing as the association rate constant, ka. In general, 
the larger the Ka, the stronger the Kb, and the smaller the Kd (equilibrium dissociation constant), 
the stronger Kb. The larger Kb corresponds to a stronger binding effect. Dissociation 
constants, Kd, are the reciprocal of association constants, and the smaller number is the stronger 
binding effect. From Eq. (1), the plot of DμA/[B] versus DμA should be linear, and Kb can be 
obtained from its slope. Numerous review articles have appeared in the past decade to describe 
ACE for the determination of Kb, and the excellent, pioneering work of Whitesides, Chu, Walsh, 
Karger, and others, should be studied [47], [48], [49] and [50]. 
Our purpose in these studies has been to estimate the Kb values for various Abs (commercial and 
private) towards the prion protein, PrPc, of a commercial source. There is, of course, a 
fundamental interest in knowing the Kb values for prion Abs, since the stronger the Kb, then 
presumably the better ELISA or other immunoassays will perform and the lower the limit of 
detection (LOD). It is useful to compare Kb values for the prion Abs, though few of these have 
already appeared in the literature [32], [33], [34] and [35]. Ideally, in the future, all 
immunoassays for prion proteins will use the very best Abs, those having the strongest Kbvalues. 
That is the main reason for determining Kb values for these or other Abs. 
Prior to measuring the Kb for a prion Ab, we first validated the basic ACE method by using a 
model system, BSA and anti-BSA Ab. In this first study, goat anti-BSA Ab was added in varying 
concentrations into the running buffer, and a fixed concentration of BSA was injected into the 
capillary. The changes in the migration times of BSA was measured. In order to monitor the EOF 
in each run, DMF was coinjected with BSA, as a neutral marker. A high concentration of a 
zwitterionic compound, Z1-CH3 was added to the running buffer, in order to eliminate 
interactions between the capillary walls and the proteins present (injected or in the buffer). ACE 
can be performed at various pH values, depending on how the injected protein migrates. The 
ideal pH, where the injected protein is well resolved from the neutral marker peak and elutes 
within a reasonable timeframe, must be experimentally derived. In the case of BSA, the ideal pH 
was about 6.8, where BSA was negatively charged and the Ab was almost neutral. Relative 
migration time or mobility is again defined as the difference between that for BSA and DMF. Of 
course, the faster the mobility, the shorter the overall migration times. The migration time for 
BSA should be larger than its complex, since the charge/mass ratio of the complex (AB) 
increased. Absolute values of migration time changes could not be used, since the EOF was not 
constant, as the Ab concentrations in the buffer changed. However, the relative migration 
changes (from one Ab concentration to the next) were comparable. That data showed that the 
relative migration time differences decreased with an increase of Ab concentration in the buffer. 
Using the plot of DμA/[B] versus DμA, a linear relationship was obtained, Fig. 7. From this 
plot, it was possible to derive the Kb for BSA, against this polyclonal Ab, goat anti-BSA, and this 
was 1.1 × 107 M−1 at pH 6.8. 
 
Fig. 7. A Scatchard plot of BSA with goat anti-BSA Ab, using ACE techniques to derive Kb. 
Specific conditions indicated in Section 2. 
In order to confirm this Kb for the BSA–Ab pair by the ACE method, we used an alternative 
approach, sometimes termed CZE stoichiometry [45] and [57]. In this approach, varying molar 
ratios of Ab to BSA were mixed pre-injection, to form the usual complexes. The mixture was 
then analyzed by direct CZE. Kb was then calculated from the peak areas observed. For the very 
same Ab and BSA, we determined the Kb values to be Kb0 = 3.58 × 107 M−1, Kb1 = 3.26 × 
107 M−1, Kb2 = 2.13 × 107 M−1. Several different complexes are possible for most Ags and their 
Abs, depending on the type of Ab studied. With polyclonal Abs, several binding sites on the 
same Ag molecule are possible, and thus several Kb values can be derived, as in this instance. 
However, ACE only provides a single Kb, since only one peak in the electropherogram is being 
measured as it changes its mobility and migration times with changes in Ab concentrations in the 
buffer. Nevertheless, there was a good agreement between the Kb found here via ACE and that 
using CZE stoichiometry. These numbers for Kb were also consistent with those in the literature 
(ca. 107 M−1), that have been determined by immunoprecipitation methods [57]. Thus, it was 
clear, as others had shown for Ab–Ag pairs using microchip ACE methods, that the basic ACE 
approach, based on mobility changes, was suitable to derive Kb values for Ab–Ag pairs, despite 
the fact that most previous applications of ACE methods have not been applied to Ab–Ag 
systems [47], [48], [49] and [50]. 
We next applied the same ACE method to derive the Kb values for the prion protein and various 
Abs, mainly commercial in nature. Fig. 8 illustrates the various electropherograms realized for a 
Rubenstein Ab (O1-16/6BIO anti-prion Ab) injected into varying concentrations of the prion 
protein. We have now reversed the protein injected versus that in the running buffer, mainly for 
the purpose to discern the peak changes. In some instances, the Ab or its Ag migrated too close 
to the EOF marker (DMF), making it unusable to deriveKb. In that instance, reversal of the 
injection protein can lead to valid Kb measurements. There is no absolute requirement as to 
which protein should be injected and which should be varied in the buffer. A main requirement 
for the ACE method to function, is that the CE peak shifts be separated from the EOF marker 
peaks, as suggested above. In this instance, it was not possible to inject the prion protein, but 
injecting the Ab proved to be entirely viable. When attempting to use the prion protein for 
injections, it always migrated (at any pH) too close to the EOF marker to observe changes in 
mobility as the [Ab] in the buffer was varied. Fig. 9 (VMRD-F99/97.6.1 anti-prion Ab) is a 
similar pattern of changing Ab migration times versus DMF, again as a function of changes in 
the prion concentration in the running buffer. 
 
Fig. 8. A series of ACE electropherograms for the Rubenstein Ab. The running buffer consisted 
of 50 mM sodium phosphate and various concentrations of the prion protein, PrPc, pH 8.5. The 
sample of Ab was 0.4 μM with 0.005% DMF in water. Other experimental conditions are 
described in Section 2. 
 
Fig. 9. A series of ACE electropherograms for the VMRD Ab. Experimental conditions as in Fig. 
8. 
In these two studies, with two different prion Abs, the running buffer contained differing 
concentrations of the prion protein, and the Ab was injected with a neutral (DMF) marker. 
However, in order to discern the Ab peak at all, the pH had to be set at 8.5, very close to the 
prion protein's pI. If the pH was lowered, to say 7.8 or even 7.4, then the Ab peak migrated too 
close to that of DMF (or any other species having just EOF), and made it impossible to measure 
the changes in migration times. At the basic pH of 8.5, the Ab was negatively charged and the 
prion protein was close to neutral. Thus, as compared to the BSA case, at this pH, the mobility of 
the Ab was decreased (shorter migration times) with an increase of the prion protein 
concentration in the running buffer. Using the same Scatchard plots as for BSA, Fig. 10 and Fig. 
11, we derived Kb values as being 1.8 × 107 M−1 for the Rubenstein Ab and 1.9 × 107 M−1 for 
the VMRD Ab. These were quite similar to the Kbvalues reported for BSA, but somewhat 
different from those already reported for different Abs towards the prion 
protein [32], [33], [34] and [35]. However, the studies by Safar et al. were done at pH 7.4 in TBS 
or MES buffered saline. 
 
Fig. 10. Scatchard plot for the Rubenstein Ab, using the data from Fig. 8. 
 
Fig. 11. Scatchard plot for the VMRD Ab, using the data from Fig. 9. 
It has been pointed out already that the prion protein (PrPc) undergoes pH-induced 
conformational transitions and aggregation at other pH values (above 8.0), thus changing its 
affinity and Kb for any Abs [58]. Our Kbvalues derived, at a more basic pH, are thus not directly 
comparable with any derived at a more neutral pH, such as 7.4–7.7. Indeed, it could be argued 
that Kb values measured at a pH far away from that used for immunoassays (typically, neutral, 
7.4–7.7), will not be comparable to those determined at neutral pH values. And, Kb values 
determined at pH values away from those used for immunoassays, cannot be directly used to 
predict LODs or efficiencies in such immunoassays. Then, why determine Kb values at any pH 
away from neutral values? In the case of ACE, this is a very real drawback, because not all pH 
values can be employed, as above for the prion Abs, but not for the BSA case. Migration times 
change with pH in ACE as in CZE, and if changes in migration times are needed to derive Kb, 
then without the ability to measure migration time changes at a given pH, nothing further can be 
derived. And, if a neutral pH is needed to derive Kb values that relate to immunoassay 
applications, that pH must permit for determination of migration time changes and 
thus, Kb derived. Again, ACE cannot function in all Ab–Ag instances at all pH values, and one 
must take this into consideration when attempting to derive the Kb at a specific pH value. 
4. Conclusions 
In this study, we have attempted to utilize both cIEF and ACE to derive information about prion 
Abs. The cIEF, as expected, has shown us the complexity of certain Ab species, the number of 
isoforms present, their pI values, and the homogeneity of such species against a target Ag. cIEF 
has also allowed us to determine which isoforms in a mixture were active towards the same Ag, 
using mobility changes and shifts, as in flat-bed gel electrophoresis. This can also be used to 
demonstrate Ab–Ag activity and recognition, by changes in pI values for the complexes. cIEF 
can also show approximately how many complex peaks are formed for any given Ab–Ag pair. 
Thus, cIEF, as shown by others for commercial Abs, can be quite useful in studying Ab–Ag 
interactions, recognition, and complex formation. 
In the case of ACE, we have utilized this basic approach to determine Kb values for BSA and two 
prion Abs. With smaller and smaller Kd values, one obtains larger and larger Kb values. And, 
with larger Ka values, one also obtains larger Kb. The value of Kb is really determined by the two, 
opposing equilibrium constants, association and dissociation, of the complex between Ab and 
Ag. Binding equilibria are determined by the relative strengths of the complex formed (Ab–Ag) 
versus the free Ab and Ag. Factors such as size of the Ab and Ag, ionic bonds possible, pH, 
organic content of the buffer, and even temperature, can all affect the finalKb. It would be ideal 
to control the Kb for any given Ab–Ag pair, but other than for experimental conditions, this has 
yet to be realized. 
There are inherent limitations in all analytical methods, and ACE is not an exception. ACE can 
indeed provide Kb values for all/any Abs, but at times there are limitations in what pH values can 
be used with any given Ab–Ag pair. It is possible to reverse the placement of the Ab–Ag pair, 
that being injected or that having varying concentrations in the running buffer. Valid Kb values 
can be derived for the prion Abs, at certain pHs, but if those pH values are far away from the pH 
needed to perform immunoassays, then the Kb cannot be readily used to predict efficiency of 
operation or LODs in such immunoassays, when performed at a different pH. And, that is the 
crux of the ACE matter for Ab–Ag pairs. The greatest value, in our opinion, is to derive aKb at a 
neutral pH commonly used for immunoassays, for only then can Kb values be compared from 
study-to-study, when they are derived at the same or a close pH value. 
5. Nomenclature 
Ab  antibody 
Abs  antibodies 
Ag  antigen 
Ab–Ag antibody–antigen complex(es) 
ACE  affinity capillary electrophoresis 
anti-BSA  antibody to BSA 
[B]  concentration of binding ligand in ACE, B (sometimes termed L) 
BSA  bovine serum albumin 
CZE  capillary zone electrophoresis 
CE  capillary electrophoresis 
cIEF  capillary isoelectric focusing 
dt  change in migration times (d = delta) 
DμA,B differences in migration times for A in presence of varying concentrations of B 
(binding ligand)(D = delta) 
EPF  electrophoretic flow or force 
EOF  electroosmotic flow 
EPF  electrophoretic migration force 
ELISA  enzyme-linked immunosorbent assay 
FL  fluorescence detection 
IACE  immunoaffinity ACE 
i-PCR  immuno-polymerase chain reaction 
Ka  affinity constant 
Kb  binding constant 
L  ligand binding to receptor, A 
[L]  concentration of ligand binding to receptor, A 
LOD  limit of detection 
log % (w/w) natural logarithm of mass percent 
Mr  molecular mass 
M−1  1/molar concentration or 1/molarity 
MWCO molecular mass cut-off (microfiltration) 
NYS-IBR New York State Institute for Basic Biomedical Research (Staten Island, NY, 
USA) 
PCR  polymerase chain reaction 
pH  −log [hydronium ion] 
%RE  percent relative error 
RE  relative error 
tR  retention or migration time in ACE 
SDS  sodium dodecyl sulfate 
SPR  surface plasmon resonance 
TOF-MS time-of-flight mass spectrmetry 
% (w/w) mass percent 
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